Everolimus for the treatment of advanced gastrointestinal or lung nonfunctional neuroendocrine tumors in East Asian patients: a subgroup analysis of the RADIANT-4 study

BACKGROUND: In RADIANT-4, everolimus showed an improvement of 7.1 months in median progression-free survival (PFS) vs placebo among patients with advanced, well-differentiated, nonfunctional neuroendocrine tumors (NETs) of gastrointestinal (GI) or lung origin. The present analysis focuses on the eff...

詳細記述

保存先:
書誌詳細
出版年:Onco Targets Ther
主要な著者: Yao, James C, Oh, Do-Youn, Qian, Jiaming, Park, Young Suk, Herbst, Fabian, Ridolfi, Antonia, Izquierdo, Miguel, Ito, Tetsuhide, Jia, Liqun, Komoto, Izumi, Sriuranpong, Virote, Shimada, Yasuhiro
フォーマット: Artigo
言語:Inglês
出版事項: Dove Medical Press 2019
主題:
Original Research
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC6400121/
https://ncbi.nlm.nih.gov/pubmed/30881026
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S182259
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料